Irving L. Weissman
Stanford University
1170 Papers
18.9K Citations
Irving L. Weissman is an academic researcher from Stanford University. The author has contributed to research in topics: Stem cell & Haematopoiesis. The author has an hindex of 201, co-authored 1141 publications. Previous affiliations of Irving L. Weissman include Eli Lilly and Company & Memorial Sloan Kettering Cancer Center.
Chat about Author
Papers
Retroviral Transduction of FACS-Purified Hematopoietic Stem Cells.
TL;DR: This "classical" method utilizes preconditioned bone-marrow cells and coculture of these cells with virus-producing packaging cells in the presence of exogenous cytokines to yield high proportions of transduced cells that can repopulate lethally irradiated recipient mice for long periods of time.
2
Publisher Correction: Notch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma.
Suzana Assad Kahn,Xin Wang,Ryan T. Nitta,Sharareh Gholamin,Johanna Theruvath,Gregor Hutter,Tej D. Azad,Lina Wadi,Sara Bolin,Sara Bolin,Vijay Ramaswamy,Rogelio Esparza,Kun Wei Liu,Michael S. B. Edwards,Fredrik J. Swartling,Debashis Sahoo,Gordon Li,Robert J. Wechsler-Reya,Jüri Reimand,Jüri Reimand,Yoon Jae Cho,Michael D. Taylor,Irving L. Weissman,Siddhartha Mitra,Samuel H. Cheshier +24 more
TL;DR: The original version of this Article omitted Suzana A. Kahn, Siddhartha S. Mitra & Samuel H. Cheshier as jointly supervising authors.
Patent
Combination therapy for treatment of coronary artery disease
Nicholas J. Leeper,Irving L. Weissman +1 more
- 25 Feb 2016
TL;DR: In this paper, an effective combined dose of an anti-CD47 agent and anti-TNF agent is administered to the subject in a dose and for a period of time effective to stabilize, prevent or reduce atherosclerotic plaque in the individual.
2
Patent
Method and compositions for modulating lifespan of hematolymphoid cells
Irving L. Weissman,Eric Lagasse +1 more
- 22 Feb 1994
TL;DR: In this paper, the lifespan of progeny cells of mammalian hematopoietic stem cells, particularly myeloid series cells, was modelled for modifying the lifespan.
2